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	  Objective(s):	We	 investigated	 the	 contribution	of	gyrA	 and	parC	mutational	mechanism	 in	decreased	
ciprofloxacin	susceptibility	of	Acinetobacter	baumannii	isolated	from	burn	wound	infections.	
Materials and Methods: Ciprofloxacin	susceptibility	of	50	A.	baumannii	isolates	was	evaluated	by	disk	
diffusion	and	agar	dilution	methods.	PCR	and	sequencing	were	performed	for	detection	of	mutation	in	
gyrA	and	parC	genes.	
Results: The	 44	 and	 4	 isolates	 of	 A.	 baumannii	 exhibited	 full	 and	 intermediate‐resistant	 to	
ciprofloxacin,	 respectively.	 Overall,	 the	 42	 isolates	 with	 double	 mutations	 of	 gyrA	 and	 parC	 genes	
showed	a	higher	level	of	ciprofloxacin	resistance	than	the	3	isolates	with	single	mutations	of	gyrA	or	
parC.	
Conclusion:	Simultaneous	mutations	in	gyrA	and	parC	genes	are	expected	to	play	a	major	role	in	high‐
level	 fluoroquinolone	 resistance	 in	A.	baumannii;	 albeit	 a	 single	mutation	 in	DNA	 topoisomerase	 IV	
could	occasionally	be	associated	with	intermediate‐resistance	to	these	antimicrobials.	
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Introduction	
A	 list	 of	 organisms	 has	 been	 identified	 by	 the	
Infectious	 Disease	 Society	 of	 America	 as	 being	
responsible	 for	 the	 majority	 of	 healthcare	 associated	
drug	 resistant	 infections.	 These	 organisms	 are	 the	
members	 of	 the	 notorious	 "ESKAPE"	 (Enterococcus	
faecium,	Staphylococcus	aureus,	Klebsiella	pneumoniae,	
Acinetobacter	baumannii,	Pseudomonas	aeruginosa,	and	
Enterobacter	 species)	 (1).	 Among	 these	 problematic	
organisms,	A.	 baumannii	 has	 nowadays	 emerged	 as	 a	
particular	concern	worldwide;	because	it	is	responsible	
for	 a	 variety	 of	 infections,	 such	 as	 blood	 infection,	
meningitis,	 ventilator	 associated	 pneumoniae	 (VAP),	
and	 wound	 infections,	 especially	 among	 patients	
admitted	 in	 burn	 and	 intensive	 care	 units	 (2,	 3).	 In	
addition,	 this	 organism	 is	 a	 successful	 pathogen	 to	
escape	 the	 effects	 of	 several	 classes	 of	 antimicrobials,	
including	fluoroquinolones	and	represents	a	significant	
challenge	to	infectious	disease	specialists	(4).			
The	 antimicrobial	 activity	 of	 fluoroquinolones	 is	
to	 form	ternary	complexes,	 including	enzymes,	such	
as	DNA	gyrase	 or	 topoisomerase	 IV,	 drug,	 and	DNA	
which	 can	 block	 DNA	 replication	 and	 transcription,	
probably	 before	 DNA	 cleavage	 occurs	 (5).	 There	 is	
remarkable	conservation	of	protein	sequences	between	
the	DNA	gyrase	subunit	A	(GyrA)	and	topoisomerase	IV	
subunit	 C	 (ParC)	 in	 the	 quinolone	 resistance	
determining	 region	 (QRDR).	 Resistance	 to	
fluoroquinolone	 in	 bacteria	 is	 mediated	 mainly	 by	
spontaneous	mutations	 in	the	QRDR	of	gyrA	and	parC	
genes	 (8).	 In	 Escherichia	 coli,	 the	 most	 important	
mutations	 leading	 to	 a	 quinolone‐resistant	 phenotype	
are	 Ser83Leu	 and	 Asp87Asn	 in	 the	 gyrA	 gene,	 and	
Ser80Arg	and	Glu84Val	in	the	parC	gene	(6,	7).	
Many	 fluoroquinolone‐resistant	 A.	 baumannii	
clinical	isolates	have	been	reported	in	Iran	(8‐9).	There	
are,	 however,	 few	 studies	 about	 the	 prevalence	 of	
mutations	 in	 the	 genes	 for	 DNA	 gyrase	 and	
topoisomerase	 IV	 in	 this	 organism.	 So,	 the	 present	
study	 aimed	 to	 specifically	 assess	 the	 presence	 of	
mutations	in	the	gyrA	and	parC	genes	and	their	effects	
on	 resistance	 to	 fluoroquinolones	 in	 A.	 baumannii	
isolates	from	patients	at	a	teaching	hospital	in	Tehran.				
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Materials	and	Methods	
Bacterial	isolates	
Motahari	Hospital	 is	a	120‐bed	university	affiliated	
Burn	 and	 Reconstruction	 Center	 located	 in	 Tehran,	
Iran.	A	total	of	50	non‐repetitive	A.	baumannii	 isolates	
were	 recovered	 between	 April	 2012	 and	 March															
2013	 from	 burn	 wounds	 of	 patients	 admitted	 in	 this	
hospital.	All	 isolates	were	assigned	to	A.	baumannii	by	
bacteriologic	 and	 traditional	 phenotypic	 methods,	
including	 gram's	 staining,	 oxidase	 and	 catalase	 tests,	
motility,	 oxidative‐fermentative	 (OF)	 test,	 and	 growth	
at	37	 C	and	44	 C.	The	PCR	of	 the	 intrinsic	blaOxa‐51‐like	
gene	was	done	to	confirm	A.	baumannii	species	(10).	
	
Antimicrobial	susceptibility	testing	
The	 susceptibility	 of	 A.	 baumannii	 isolates	 to	
ciprofloxacin	disk	(5	µg)	(Mast,	Merseyside,	U.K)	was	
assessed	by	the	standard	disk	agar	diffusion	method	
on	 Mueller	 Hinton	 agar	 plates.	 The	 MIC	 for	
ciprofloxacin	 was	 determined	 by	 the	 broth	
macrodilution	method	 in	 accordance	 to	 the	 Clinical	
and	 Laboratory	 Standards	 Institute	 (CLSI)	 criteria	
(11).	 Briefly,	 a	 serial	 dilutions	 of	 ciprofloxacin	 was	
prepared	 in	 Mueller	 Hinton	 broth	 tubes	 with	 the	
bacteria	 at	 a	 density	 of	 5106	 CFU/ml.	 Microbial	
tubes	were	 incubated	at	37	 C	 for	18	hr	 and	 finally,	
the	lowest	concentration	of	antibiotic	with	no	visible	
bacterial	 growth	 was	 defined	 as	 the	 MIC.	 Quality	
control	 was	 done	 using	 Pseudomonas	 aeruginosa	
ATCC	 27853	 strain,	 and	 results	 were	 compared	 to	
MIC	 ranges	 of	 CLSI.	 A.	 baumannii	 isolates	 were	
considered	 as	 intermediate‐resistant	 and	 full‐
resistant	to	ciprofloxacin	when	the	MIC	was	2	µg/ml	
and	4	µg/ml,	respectively.	
	
PCR	amplification	and	sequencing	
The	 QRDRs	 of	 the	 gyrA	 and	 parC	 genes	 in	 A.	
baumannii	 clinical	 isolates	 were	 amplified	 by																			
PCR	 assay.	 Two	 pairs	 of	 oligonucleotide	 primers																		
used	 for	 the	 PCR	 reactions	 were	 gyrA	 primer:												
forward,	5'‐AAATCTGCTCGTGTCGTTGG‐3';	 reverse,	5'‐
GCCATACCTACAGCAATACC‐3',	 and	 parC	 primer:	
forward,	 5'‐AAGCCCGTACAGCGCCGTATT‐3';	 reverse,	
5'‐AAAGTTATCTTGCCATTCGCT‐3'.	 Extraction	 of	
genomic	 DNA	 from	 A.	 baumannii	 colonies	 was	
performed	 using	 genomic	 DNA	 purification	 kit	
(Fermentas,	 Germany),	 based	 on	 the	 manufacturer's	
instructions.	 	 For	 all	 amplification	 reactions,	 a	 PCR	
mixture	was	used	that	contained	12.5	µl	of	2	Master	
Mix	(Ampliqon,	Denmark),	including	1	PCR	buffer,	1.5	
mmol/l	MgCl2,	dNTPs	at	a	concentration	of	0.15	mmol/l 
each	dNTP,	1.25	U	of	Taq	DNA	polymerase,	0.5	µl	of	0.8	
µM	of	each	primer,	1	µl	of	template	DNA	(0.5	µg),	and	
sterile	 distilled	 water	 up	 to	 25	 µl.	 DNA	 amplification	
was	performed	in	the	Mastercycler	gradient	instrument	
(Eppendorf,	 Germany).	 For	 gyrA,	 PCR	 conditions	
consisted	of	an	 initial	denaturation	at	95	 C	for	1	min;	
35	cycles	of	denaturation	at	95	C 	for	of	30	sec,	30	sec	
of	annealing	at	52	 C,	and	2	min	of	extension	at	72	 C;	
ending	with	a	final	extension	at	72	 C	for	10	min.	The	
temperature	 profile	 for	 parC	 gene	 was	 comprised of											
95	C	for	2	min,	followed	by	35	cycles	of	1	min	at	95	C,	
1	min	at	60	C	and	2	min	at	72	C,	with	10	min	at	72	C	
for	final	extension	step.	DNA	fragments	were	analyzed	
by	 electrophoresis	 on	 agarose	 gel	 (2%,	 wt/vol)	
containing	 0.5	 mg	 of	 ethidium	 bromide	 per	 liter	 and	
photographed	 with	 ultraviolet	 illumination.	 Direct	
sequencing	of	the	PCR	products	in	both	directions	was	
performed												by	using	an	ABI3730XL	DNA	analyzer	
(Applied	 Biosystems,	 Forster,	 USA).	 Nucleotide	
sequences	 data	were	 analyzed	 at	 the	 National	 Center	
for	Biotechnology	 Information	 (NCBI),	available	at	 the	
website	(http:/www.ncbi.nlm.nih.gov/BLAST/).	
	
Statistical	data	analysis	
SPSS	 version	 11.5	 (SPSS,	 Inc.,	 Chicago,	 IL,	 USA)	
was	 employed	 for	 statistical	 analysis.	 Descriptive	
statistics	and	Pearson's	chi‐square	tests	were	used	to	
evaluate	 correlation	 between	 mutation	 and	
ciprofloxacin	 resistance.	 Statistical	 significance	 was	
defined	as	P‐value	less	than	0.05.		
	
Results	
Ciprofloxacin	 susceptibility	 and	 amino	 acid	
substitutions	
The	 susceptibility	 testing	 by	 disk	 diffusion	
method	 determined	 that	 4%,	 8%,	 and	 88%																									
of	A.	 baumannii	 clinical	 isolates	were	 susceptible,
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.	PCR	amplification	of	the	QRDRs	of	the	gyrA	(A)	and	parC	(B)	genes	in	Acinetobacter	baumannii	isolates.	Lanes:	1‐	7,	PCR	products	
of	the	corresponding	genes;	M,	100	bp	Plus	DNA	Ladder	
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Table	1.	Point	mutations	in	the	QRDRs	of	the	gyrA	and	parC	genes	of	Acinetobacter	baumannii	 isolates,	and	the	ciprofloxacin	MIC	in	the	
isolates	of	mutation	groups	 
	
Mutation	
group	
No.	(%)	of	
isolates	
No.	(%)	of	isolates	with	MIC	(µg/ml)	to	ciprofloxacin
			2														4												8												16												32												64													128										128	
				gyrAmutations																									parC	mutations
	
	S83	(tca)					G81(ggt)									S80(tcg)					E84(gaa)				G78(ggt)	
I	 1	(2.2)	 1	(2.2)	 		L	(tta)
II	 2	(4.4)	 															2	(4.4) 																																																																																											 	C (tgt)
III	 17	(37.8)	 																																												2	(4.4)				4	(8.9)				 7	(15.6)			 2	(4.4)					 2 (4.4) 		L	(tta)																																				L	(ttg)	
IV	 6	(13.3)	 																											 1	(2.2)																			1	(2.2)					1	(2.2)					 	2	(4.4)				 1 (2.2) 																							D	(gat)														L	(ttg)	
V	 19	(42.2)	 																																																												3	(6.7)			 10	(22.1)	 	3	(6.7)					 3 (6.7) 		L	(tta)													 																																										K	(aaa)
	 	 	 	
intermediate‐resistant	 and	 full‐resistant	 to	 cipro‐
floxacin,	respectively.	The	MIC	range	of	ciprofloxacin	in	
44	 full‐resistant	 isolates	 was	 4	 to	 128	 µg/ml.																
To	 determine	 the	 changes	 in	 the	 structure	 of	 DNA	
gyrase	 and	 topoisomerase	 IV	 enzymes,	 the	 QRDRs	 of	
corresponding	genes,	gyrA	and	parC,	were	analyzed	by	
PCR	 sequencing	 technique	 in	 all	 50	 clinical	 isolates		
with	 intermediate‐resistant	 and	 full‐resistant	 to	
ciprofloxacin.	 Amplification	 of	 gyrA	 and	 parC	 genes	
yielded	PCR	products	of	349	and	327	bp,	 respectively	
(Figure	1).	The	nucleotide	sequencing	results	revealed	
that	 45	 (90%)	 of	 the	 50	 isolates	 had	 amino	 acid	
alteration	in	gyrA	and	parC,	as	follow:	1	(2.2%)	isolate	
in	 gyrA	 only,	 2	 (4.4%)	 isolates	 in	 parC	 only,	 and																					
42	 (93.3%)	 isolates	 in	 gyrA	 and	 parC,	 concurrently.																			
The	A.	baumannii	isolates	were	divided	into	five	groups	
based	 on	 the	 amino	 acid	 substitutions	 associated															
with	 resistance	 to	 fluoroquinolone	 (Table	 1).	 Single	
mutations	 encoding	 Ser83Leu	 and	 Gly81Asp	 were	
found	in	the	QRDR	of	gyrA	in	37	(82.2%)	and	6	(13.3%)	
of	 the	 45	mutated	 isolates,	 respectively.	 Forty	 four	 of	
the	 45	 Acinetobacter	 isolates	 (95.5%)	 had	 a	 single	
mutation	 in	 parC	 encoding	 Ser80Leu	 (23;	 51.1%),	
Glu84Lys	(19;	42.2%),	and	Gly78Cys	(2;	4.4%).	
	
MIC	for	ciprofloxacin	in	the	QRDR	mutants	
Groups	I	and	II	mutants	had	a	single	mutation	in	
gyrA	 and	 parC,	 respectively;	 but	 their	 ciprofloxacin	
MIC	ranged	from	2	to	4	µg/ml.	Acinetobacter	isolates	
present	in	the	mutation	groups	III,	IV,	and	V	showed	
double	 mutations	 in	 gyrA	 and	 parC	 and	 were	
resistant	 to	 ciprofloxacin	 with	 a	 MIC	 range	 of	 8	 to	
128	µg/ml.	Overall,	 isolates	with	double	mutations	
of	 gyrA	 and	 parC	 genes	 showed	 a	 higher	 level	 of	
ciprofloxacin	 resistance	 than	 isolates	 with	 single	
mutations	of	gyrA	or	parC	(P<	0.05).	
	
Nucleotide	sequence	accession	number	
The	 nucleotide	 sequences	 data	 reported	 in	 the	
present	 study	 have	 been	 deposited	 in	 the	
Pubmed/NCBI/GenBank	nucleotide	sequence	database	
under	 accession	 numbers	 for	 gyrA	 (KJ195830.1	 and	
KJ195831.1)	 and	 parC	 (KJ756512,	 KJ756513	 and	
KJ756514)	genes.		
			
Discussion	
Previous	 studies	 have	 shown	 that	 fluoroquino‐
lones	 are	 one	 of	 the	 first	 line	 therapies	 for	 A.	
baumannii	 infections	 (12,	 13).	However,	 our	 results	
in	 agreement	 with	 other	 studies	 revealed	 a	
considerable	increase	in	ciprofloxacin	resistance	in	Iran	
(8,	 9).	 Resistance	 to	 ciprofloxacin	 in	 Acinetobacter	
isolates	 is	 alarming;	 since	 many	 of	 such	 strains	 are	
usually	 multi‐drug	 resistant	 (MDR),	 and	 at	 these	
circumstances,	 the	 remaining	 therapeutic	 options	 are	
colistin	 (a	 relatively	 toxic	 drug),	 tigecycline	 (a	
bacteriostatic	 agent,	 i.e.	 a	disadvantage	when	using	 in	
immunocompromised	patients),	and	sulbactam	(with	a	
limited	antibacterial	spectrum	only)	(14).					
It	 is	 accepted	 that	 changes	 in	 the	 structure																			
of	 the	 antibiotic	 targets	 DNA	 gyrase	 and	 DNA	
topoisomerase	 IV	 are	 one	 of	 the	 most	 significant	
mechanisms	 in	 conferring	 a	 resistance	 to	
fluoroquinolone	 in	 gram	 negative	 bacilli	 (7).	 In																		
E. coli,	three	or	four	mutations	in	both	gyrA	and	parC	
genes	are	necessary	to	obtain	high‐level	resistance	to	
ciprofloxacin,	even	as	double	mutations	at	positions	
83	(Ser83)	of	gyrA	and	80	(Ser80)	of	parC	cause	only	
moderate‐level	 resistance	 (6,	 7).	 Nevertheless,	 the	
situation	in	A.	baumannii	is	rather	different	from	that	
in	E.	 coli,	 since	 we	 found	 in	 the	 present	 study	 that	
only	 a	 double	 mutation	 could	 lead	 to	 high‐level	
resistant	phenotype.	So	that,	among	44	ciprofloxacin‐
resistant	 isolates,	 11	 (25%)	 had	MIC	 range	 of	 8‐32	
µg/ml	 and	 the	majority	 (31;	 70.4%)	 of	 isolates	 had	
MICs	 of	 128	 µg/ml	 or	 higher,	 that	 indicate	 these	
isolates	are	highly	resistant	to	fluoroquinolones.	
		Our	 sequencing	 results	 revealed	 serine	 to	
leucine	 mutation	 at	 position	 83	 of	 gyrA	 subunit	 in													
38	 of	 44	 ciprofloxacin‐resistant	 Acinetobacter	
isolates.	 	 Similar	 to	 study	 by	 Park	 et	al	 (15),	 this	 is	
indicative	 of	 the	 fact	 that	 Ser83Leu	 substitution	 is	
the	principal	mutation	in	A.	baumannii	for	resistance	
to	 fluoroquinolones.	 Other	 mutations	 in	 the	 gyrA	
gene	 resulting	 in	 Ala84Pro	 or	 Gly81Val	 reported	 in	
ciprofloxacin	resistant	isolates	of	previous	study	(16)	
were	not	observed	 in	our	 included	 isolates.	 Instead,	
we	found	a	novel	mutation	in	the	gyrA	gene,	leading	
to	Gly81Asp	substitution	DNA	gyrase,	in	six	resistant	
isolates	with	a	MIC	range	at	8	to	128	µg/ml.	
In	A.	 baumannii,	 topoisomerase	 IV	 is	 a	 target	 of	
quinolones	 and	 mutations	 at	 residues	 Ser80	 and	
Glu84	 of	parC	 contribute	 to	 decreased	 fluoroquino‐
lone	 susceptibility	 (16).	 Although	 parC	 mutations	
always	 along	with	mutations	 in	gyrA	 are	 needed	 to	
acquire	a	high‐level	resistance	to	quinolones	(4),	two	
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clinical	 isolates	 in	 our	 study	 had	mutations	 in	parC	
without	gyrA,	suggesting	that	parC	might	not	only	be	
a	 secondary	 target	 for	 quinolones	 but	 is	 really	 as	
important	as	gyrA	to	cause	a	decreased	susceptibility	
to	 fluoroquinolones	 in	 A.	 baumannii.	 On	 the	 other	
hand,	QRDRs	of	the	three	isolates	with	intermediate‐
resistance	 to	 ciprofloxacin	 in	 the	 current	 study	 did	
not	possess	alterations	associated	with	fluoroquino‐
lones	 resistance	 in	 the	 sequence	 of	 either	 genes,	
indicating	 other	 resistance	 mechanisms,	 such	 as	
efflux	systems	should	be	considered	in	these	isolates	
(17).			
	
Conclusion	
Although	a	 single	point	mutation	 in	DNA	gyrase	 is	
enough	 for	 resistance	 to	 fluoroquinolone	 in	 A.	
baumannii,	 the	 concurrent	 mutations	 within	 QRDR	
regions	 of	 the	 gyrA	 and	 parC	 genes	 are	 expected	 to	
significantly	 contribute	 to	 high‐level	 fluoroquinolone	
resistance.	 Further	 studies	 are	 required	 to	 elucidate	
mechanisms,	 other	 than	 alterations	 in	 gyrA	 and	parC,	
leading	 to	decreased	susceptibility	 to	quinolones	 in	A.	
baumannii	isolates.	
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